Share:
Original Article

Eccrine Porocarcinoma of the face is a great imitator with aggressive behavior

Author Affiliation(s)

Abstract

Introduction: Eccrine porocarcinoma (EPC) is a rare subtype of non-melanoma skin cancer developing in the intraepithelial portion of eccrine sweat glands. It is branded with a highly metastatic potential and increased rate of local recurrence after treatment. EPC showcased a trend of developing on the extremities, with presentation on the face sparse.


Objectives: Aim of the study was to evaluate the frequency, clinical features, and course of this malignancy presented on the face.


Methods: A retrospective review of the skin cancers excised between January 2010 and June 2021 was conducted in the plastic surgery department of a tertiary hospital. Patients were included in the study if EPC on the face was histologically confirmed. A prospectively maintained clinic database and the pathological reports were used to collect data.


Results: 4 EPC cases on the face out of 3984 confirmed skin cancers were identified. None of the cases was suspected clinically, but the diagnosis was established following the histopathologic examination. An aggressive postoperative behavior was confirmed in two cases.


Conclusions: The variance in the clinical presentation and the non-specific characteristics are perplexing clinical diagnosis, with the histopathologic examination representing the current standard for confirmation. Early diagnosis and adequate surgical resection are recommended as treatment cornerstones. Clinical awareness ought to be raised and a definitive treatment protocol be established for optimized results.

Keywords : eccrine porocarcinoma, skin cancer, face, sweat gland

References

1. Goldman P, Pinkus H, Rogin J. Eccrine poroma; tumors exhibiting features of the epidermal sweat duct unit. AMA Arch Derm. 1956;74(5):511-521. PMID: 13361538. 2. Robson A, Greene J, Ansari N, Kim B, Seed PT, McKee PH, Calonje E. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol. 2001;25(6):710-20. DOI: 10.1097/00000478-200106000-00002. PMID: 11395548. 3. Seretis K, Thomaidis V, Karpouzis A, Tamiolakis D, Tsamis I. Epidemiology of surgical treatment of nonmelanoma skin cancer of the head and neck in Greece. Dermatol Surg. 2010;36(1):15-22. DOI:10.1111/j.1524-4725.2009.01379.x. PMID: 19912277. 4. Salih AM, Kakamad F, Baba HO, et al. Porocarcinoma; presentation and management, a meta-analysis of 453 cases. Ann Med. 2017;20:74-79. DOI: 10.1016/j.amsu.2017.06.027. PMID: 28721214. PMCID: PMC5499034. 5. Snow SN, Reizner GT. Eccrine porocarcinoma of the face. J Am Acad Dermatol. Aug 1992;27(2 Pt 2):306-311. DOI:10.1016/0190-9622(92)70187-k. PMID: 1325487. 6. Akalin T, Sen S, Yücetürk A, Kandiloğlu G. P53 protein expression in eccrine poroma and porocarcinoma. Am J Dermatopathol. 2001;23(5):402-406. DOI: 10.1097/00000372-200110000-00003. PMID: 11801771. 7. Gu LH, Ichiki Y, Kitajima Y. Aberrant expression of p16 and RB protein in eccrine porocarcinoma. J Cutan Pathol. 2002;29(8):473-479. DOI:10.1034/j.1600-0560.2002.290805.x. PMID: 12207741. 8. Obaidat NA, Alsaad KO, Ghazarian D. Skin adnexal neoplasms—part 2: An approach to tumours of cutaneous sweat glands. J Clin Pathol. 2007;60(2):145-159. DOI:10.1136/jcp.2006.041608. PMID: 16882695; PMCID: PMC1860616. 9. Belin E, Ezzedine K, Stanislas S, et al. Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure. Br J Dermatol. 2011;165(5):985-989. DOI:10.1111/j.1365-2133.2011.10486.x. PMID: 21711331. 10. Huet P, Dandurand M, Pignodel C, Guillot B. Metastasizing eccrine porocarcinoma: report of a case and review of the literature. J Am Acad Dermatol. 1996;35(5):860-864. DOI:10.1016/s0190-9622(96)90105-x. PMID: 8912607.

Send mail to Author


Send Cancel